HIV chemotherapy.
The use of chemotherapy to suppress replication of the human immunodeficiency virus (HIV) has transformed the face of AIDS in the developed world. Pronounced reductions in illness and death have been achieved and healthcare utilization has diminished. HIV therapy has also provided many new insights into the pathogenesis and the viral and cellular dynamics of HIV infection. But challenges remain. Treatment does not suppress HIV replication in all patients, and the emergence of drug-resistant virus hinders subsequent treatment. Chronic therapy can also result in toxicity. These challenges prompt the search for new drugs and new therapeutic strategies to control chronic viral replication.
Richman
D D
DD
Veterans Affairs San Diego Healthcare System and University of California San Diego, Departments of Pathology and Medicine 0679, La Jolla, California 92093-0679, USA. drichman@ucsd.edu
D016915:AIDS Vaccines / Q000627:therapeutic use; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D003906:Developing Countries; D015195:Drug Design; D004352:Drug Resistance, Microbial; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D014779:Virus Replication / Q000187:drug effects
D016915:AIDS Vaccines; D019380:Anti-HIV Agents